Cargando…
Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial
BACKGROUND: Regular use of beta-agonists leads to tolerance to their bronchodilator effects. This can be demonstrated by measuring the response to beta-agonist following bronchoconstriction using methacholine. However most studies have demonstrated tolerance after a period of beta-agonist withdrawal...
Autores principales: | Haney, Sarah, Hancox, Robert J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1266400/ https://www.ncbi.nlm.nih.gov/pubmed/16168062 http://dx.doi.org/10.1186/1465-9921-6-107 |
Ejemplares similares
-
Overcoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trials
por: Haney, Sarah, et al.
Publicado: (2007) -
Optimal Bronchodilation for COPD Patients: Are All Long-Acting β(2)-Agonist/Long-Acting Muscarinic Antagonists the Same?
por: Miravitlles, Marc, et al.
Publicado: (2018) -
Changing patterns in long-acting bronchodilator trials in chronic obstructive pulmonary disease
por: Donohue, James F, et al.
Publicado: (2011) -
Is there a rationale and role for long-acting anticholinergic bronchodilators in asthma?
por: Price, David, et al.
Publicado: (2014) -
Short-acting β2-agonists (SABA) bronchodilator sales and outdoor mould in central France
por: Caillaud, D. M., et al.
Publicado: (2019)